Trial Search Results

Erwinase Master Treatment Protocol

The purpose of this study is to make Erwinase available to patients with acute lymphoblastic leukemia (ALL) who have had previous allergic reactions to certain formulations of L-asparaginase.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Phoenix Children's Hospital

Collaborator: Jazz Pharmaceuticals

Stanford Investigator(s):


  • Drug: Erwinia L-asparaginase




Inclusion Criteria:

   - Patient must give written informed consent to receive Erwinase.

   - Patient must be treated for acute lymphoblastic leukemia.

   - Patient must have either systemic hypersensitivity reactions to native (Elspar) or
   pegylated E.coli asparaginase (Oncaspar). This includes patients with generalized rash
   with or without anaphylactic symptoms, or patients with previously documented local or
   systemic reactions to E.coli derived L-asparaginase.

Exclusion Criteria:

   - Previous allergic reaction to Erwinia L-asparaginase (Erwinase)

   - Previous acute pancreatitis

   - Pregnant or lactating woman

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
Not Recruiting